Oppenheimer Maintains Perform on Sage Therapeutics, Lowers Price Target to $17
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Jay Olson maintains a Perform rating on Sage Therapeutics (NASDAQ:SAGE) and lowers the price target from $25 to $17.

April 18, 2024 | 1:00 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Oppenheimer maintains a Perform rating on Sage Therapeutics and lowers the price target from $25 to $17.
The reduction in price target by Oppenheimer, a reputable financial institution, could lead to a negative short-term impact on Sage Therapeutics' stock price. Investors often view such adjustments as a signal of the analyst's view on the company's future performance, potentially leading to decreased investor confidence.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100